


Correction

Correction: Nam et al. Identification of Thiazolo[5,4-*b*]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance. *Cancers* 2023, 15, 143

Yunju Nam ^{1,2,3,†}, Chan Kim ^{2,†}, Junghee Han ^{1,2,3}, SeongShick Ryu ^{1,2,3}, Hanna Cho ², Chiman Song ³, Nam Doo Kim ⁴ , Namkyoung Kim ^{1,2,3} and Taebo Sim ^{1,2,3,*}

- ¹ KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
- ² Severance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
- ³ Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea
- ⁴ Voronoibio Inc., 32 Songdogwahak-ro, Yeonsu-gu, Incheon 21984, Republic of Korea
- * Correspondence: tbsim@yuhs.ac
- † These authors contributed equally to this work.

The authors would like to make a correction to the previous article [1]. In Figure 6A, an error was introduced in the preparation of this figure for publication.

The error included:

The image treated with **6r** (0.05 μ M) in 0 h was mistakenly replaced by **6r** (0.005 μ M). The authors have provided the corrected version of the Figure 6 below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



Citation: Nam, Y.; Kim, C.; Han, J.; Ryu, S.; Cho, H.; Song, C.; Kim, N.D.; Kim, N.; Sim, T. Correction: Nam et al. Identification of Thiazolo[5,4-*b*]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance. *Cancers* 2023, 15, 143. *Cancers* **2024**, *16*, 2151. <https://doi.org/10.3390/cancers16112151>

Received: 22 May 2024
Accepted: 27 May 2024
Published: 6 June 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 6. Effects of **6r**, **6s**, **7c**, and imatinib on migration and invasion. (A) Cell migration of GIST-T1 cells was inhibited by treatment (36 h) with **6r**, **6s**, and **7c** (0.005 μ M and 0.05 μ M). (B) Invasion of GIST-T1 cells was inhibited by treatment (48 h) with **6r**, **6s**, **7c**, and imatinib (0.05 μ M). (C,D) Percentage wound healing area and relative invasion cells were calculated using ImageJ. (average \pm S.D., n = 3 one-way ANOVA and Tukey’s multiple comparisons test; * $p < 0.05$).

Reference

1. Nam, Y.; Kim, C.; Han, J.; Ryu, S.; Cho, H.; Song, C.; Kim, N.D.; Kim, N.; Sim, T. Identification of Thiazolo[5,4-*b*]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance. *Cancers* **2023**, *15*, 143. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.